The proposed bill, titled the "Right to Try Individualized Investigational Treatment Act," aims to provide patients with life-threatening or severely debilitating illnesses access to individualized investigational treatments. It establishes a new subchapter in the Arkansas Code that outlines the definitions, eligibility criteria, and procedures for patients seeking such treatments. Key definitions include "individualized investigational treatment," which refers to drugs or devices tailored to an individual based on their genetic profile, and "eligible patient," who must meet specific medical criteria and provide informed consent. The bill also details the responsibilities of physicians and manufacturers regarding the provision of these treatments.

Additionally, the bill addresses the financial aspects of accessing individualized investigational treatments, stating that manufacturers may offer these treatments without compensation or require patients to cover the associated costs. It clarifies that insurance companies are not mandated to provide coverage for these treatments but cannot deny coverage for services already included in existing contracts. The legislation also includes provisions to protect medical professionals from sanctions related to recommending or prescribing these treatments and grants immunity from civil liability for those involved in the care of patients using individualized investigational treatments, provided they comply with the law.